A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Project Information

MaxONCO

Grant agreement ID: 880194

DOI

10.3030/880194

Project closed

EC signature date 31 October 2019

Start date 1 January 2020

End date 31 December 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 979 000,00

EU contribution

€ 2 785 300,00

Coordinated by

MAXIVAX SA
Switzerland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology

Author(s): Aurelien Lathuiliere, Remi Vernet, Emily Charrier, Muriel Urwyler, Olivier Von Rohr, Marie-Claude Belkouch, Valentin Saingier, Thomas Bouvarel, Davy Guillarme, Adrien Engel, Patrick Salmon, Thomas Laumonier, Julien Grogg, Nicolas Mach
Published in: Molecular Therapy Methods & Clinical Development, Issue Volume 26, 8 Sept 2022, 2022, ISSN 2329-0501
Publisher: Cell Press
DOI: 10.1016/j.omtm.2022.07.017